Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Inclusion Criteria:

1. Must have completed a selected Novartis MS study which dosed ofatumumab 20 mg scevery 4 weeks

2. Written informed consent

Exclusion Criteria:

• Emergence of any clinically significant condition/disease during the previousofatumumab study in which study participation might result in safety risk for thesubject

• Subjects with active systemic bacterial, viral or fingal infections, or chronicinfection (e.g. AIDS)

• Subjects taking medications prohibited by the protocol

• Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusioncriteria may apply

Vaccination sub-study:

Inclusion criteria

1. Informed consent

2. Actively enrolled in the COMB157G2399 Study

3. 12 weeks of continuous treatment within the COMB157G2399 Study

4. prior vaccination history as per protocol-defined

Exclusion criteria

• known hypersensitivity or history of systemic allergic, neurologic or otherreactions to vaccines

• allergies to egg or shellfish

• any safety findings including low IgG/IgM requiring ofatumumab interruption within 12 weeks prior to vaccination sub-study start

• any major episode of infection requiring hospitalization or treatment withintravenous antibiotics within 2 weeks of the first vaccination sub-study visit

Other protocol-defined inclusion/exclusion criteria may apply